PT1751105E - Derivados de piperazina de alquil-oxindoles - Google Patents
Derivados de piperazina de alquil-oxindoles Download PDFInfo
- Publication number
- PT1751105E PT1751105E PT05745440T PT05745440T PT1751105E PT 1751105 E PT1751105 E PT 1751105E PT 05745440 T PT05745440 T PT 05745440T PT 05745440 T PT05745440 T PT 05745440T PT 1751105 E PT1751105 E PT 1751105E
- Authority
- PT
- Portugal
- Prior art keywords
- addition salts
- acid addition
- disorders
- pharmaceutically acceptable
- indol
- Prior art date
Links
- 150000005623 oxindoles Chemical class 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 208000035475 disorder Diseases 0.000 claims abstract 5
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 4
- -1 ethylenedioxy Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000008811 Agoraphobia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 208000012545 Psychophysiologic disease Diseases 0.000 claims 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 206010041250 Social phobia Diseases 0.000 claims 3
- 208000013200 Stress disease Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000003340 mental effect Effects 0.000 claims 3
- 208000019906 panic disease Diseases 0.000 claims 3
- 208000019899 phobic disease Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- AHJOSYULWRUECL-UHFFFAOYSA-N 3-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]-1,3-dihydroindol-2-one Chemical compound O=C1NC2=CC=CC=C2C1CCCCN(CC1)CCN1C1=CC=CC=N1 AHJOSYULWRUECL-UHFFFAOYSA-N 0.000 claims 1
- KATJSKRLVCHNNS-UHFFFAOYSA-N 3-[4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(N2CCN(CCCCC3C4=CC=CC=C4NC3=O)CC2)=C1 KATJSKRLVCHNNS-UHFFFAOYSA-N 0.000 claims 1
- VPHQTVYHZFPMMW-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCCCC2C3=CC=CC=C3NC2=O)CC1 VPHQTVYHZFPMMW-UHFFFAOYSA-N 0.000 claims 1
- NJGAZQPNWKVRDS-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound O=C1NC2=CC=CC=C2C1CCCCN(CC1)CCN1C1=CC(Cl)=CC2=C1OCCO2 NJGAZQPNWKVRDS-UHFFFAOYSA-N 0.000 claims 1
- AUMIDOIRKJSHQJ-UHFFFAOYSA-N 3-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-5-fluoro-1,3-dihydroindol-2-one Chemical compound O1CCOC2=C1C=C(Cl)C=C2N(CC1)CCN1CCCCC1C(=O)NC2=CC=C(F)C=C21 AUMIDOIRKJSHQJ-UHFFFAOYSA-N 0.000 claims 1
- XVVMEILIWXETCU-UHFFFAOYSA-N 5-fluoro-3-[4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(N2CCN(CCCCC3C4=CC(F)=CC=C4NC3=O)CC2)=C1 XVVMEILIWXETCU-UHFFFAOYSA-N 0.000 claims 1
- NDEQQLAZHRZSEI-UHFFFAOYSA-N 6-fluoro-3-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]-1,3-dihydroindol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2C1CCCCN(CC1)CCN1C1=CC=CC=N1 NDEQQLAZHRZSEI-UHFFFAOYSA-N 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 150000005625 indol-2-ones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Claims (16)
- ΕΡ 1 751 105/ΡΤ 1/5 REIVINDICAÇÕES 1. Derivados de 3-alquil-indol-2-ona, em que Ksem que Q é azoto; R1 e R2 independentemente representam hidrogénio ou halogéneo; R3 representa hidrogénio; R4 e R1 representam hidrogénio, e R2 representa hidrogénio; m é 4; e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 2. Derivados de 3-alquil-indol-2-ona, em que R1 e R2 independentemente representam hidrogénio ou halogéneo; R3 é hidrogénio; Q representa um grupo CH e R4 e R1 conjuntamente formam etilenodioxi, R2 representa halogéneo; m é 4; e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 3. 3-[4-(4-Piridin-2-il-piperazin-l-il)-butil]-1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 4. 3-{4-[4-(7-Cloro-2,3-di-hidrobenzo[1,4]-dioxin-5-il)- piperazin-l-il]-butil}-1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis. 1
- 5-Fluor0-3-[4-(4-piridin-2-il-piperazin-l-il)-butil]- 2 1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis. ΕΡ 1 751 105/ΡΤ 2/5 6.
- 6-Fluoro-3-[4-(4-piridin-2-il-piperazin-l-il)-butil]- 1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 7 . 3-{4-[4-(7-Cloro-2,3-di-hidrobenzo[1,4]-dioxin-5-il)-piperazin-l-il]-butil}-5-fluoro-1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 8. 3-{4-[4-(3-Metoxifenil)-piperazin-l-il]-butil}—1,3 — di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 9 . 3-{4-[4-(5-Cloro-2-metoxifenil)-piperazin-l-il]- butil}-1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 10. 5-Fluoro-3-{4-[4-(3-metoxifenil)-piperazin-l-il]-butil}-1,3-di-hidro-2H-indol-2-ona, e seus sais de adição de ácido farmaceuticamente aceitáveis.
- 11. Composições farmacêuticas que compreendem como ingrediente activo pelo menos um dos compostos de Fórmula Geral (I) de acordo com as reivindicações 1 a 10 ou um seu sal de adição de ácido farmaceuticamente aceitável, em mistura com um ou mais portador(es) ou agente(s) auxiliar convencional.
- 12. Composição farmacêutica de acordo com a reivindicação 11, adequada para o tratamento ou profilaxia de desordens do sistema nervoso central e desordens psicossomáticas incluindo sindrome de ansiedade, desordens de ansiedade particularmente generalizada, doença de pânico, doença compulsiva, fobia social, agorafobia, fobias relacionadas com situações específicas, desordens de stress, desordens de stress pós-traumático, desordem de memória pós-traumática, desordem cognitiva, disfunção sexual de origem no sistema nervoso central, depressão, esquizofrenia, neuro-degeneração seguida de declínio mental, doença de Alzheimer, icto, demências, outras doenças gastrointestinais e doenças cardiovasculares, em particular hipertensão. ΕΡ 1 751 105/ΡΤ 3/5
- 13. Processo para a preparação dos compostos de acordo com as reivindicações 1 a 10, em que R1 - R6, Q e m são como definido acima, o qual compreende a. reacção de um composto de Fórmula Geral (II),(Π) em que L é hidroxi, com um cloreto de arilsulfonilo ou um cloreto de alquilsulfonilo de cadeia linear ou ramificada possuindo 1 a 7 átomo(s) de carbono, preferivelmente cloreto de metilsulfonilo, na presença de uma base orgânica, e reacção do composto de Fórmula Geral (II) assim obtido, em que L é aril- ou alquil-sulfoniloxi, com um derivado de piridina de Fórmula Geral (III)em que R4, R5, R6 e Q são como definido acima, na presença de um agente de ligação ácido, ou b. reacçao de um composto de Fórmula Geral (V), R*(V) em que R1, R2, R3 são como definido acima, com um composto de Fórmula Geral (VI), ΕΡ 1 751 105/ΡΤ 4/5em que R4, R5, R6 sao como definido acima, m é 1, 2, 3 ou 4, L é cloro ou bromo, na presença de uma base forte.
- 14. Derivado de 3-alquil-indol-2-ona de acordo com qualquer das reivindicações 1 a 10 para utilização como medicamento.
- 15. Processo para fabrico de uma composição farmacêutica adequada para o tratamento ou profilaxia de desordens do sistema nervoso central e psicossomáticas incluindo síndrome de ansiedade, desordens de ansiedade particularmente generalizada, doenças de pânico, desordem compulsiva, fobia social, agorafobia, fobias relacionadas com situações especificas, desordem de stress, desordem de stress pós-traumático, desordem de memória pós-traumática, desordens cognitivas, disfunção sexual de origem no sistema nervoso central, depressão, esquizofrenia, declínio mental causado por citólise cerebral, doença de Alzheimer, icto, demências, outras doenças gastro-intestinais e doenças cardiovasculares, em particular hipertensão, o qual compreende a mistura de pelo menos um composto de Fórmula Geral (I) de acordo com qualquer das reivindicações 1 a 10 ou um seu sal de adição de ácido farmaceuticamente aceitável com um portador farmacêutico e opcionalmente outro agente auxiliar, e a disposição da mistura em forma galénica.
- 16. Utilização de pelo menos um composto de Fórmula Geral (I) de acordo com qualquer das reivindicações 1 a 10 ou um seu sal de adição de ácido orgânico ou inorgânico farmaceuticamente aceitável, para preparação de uma composição farmacêutica que o(s) contém, para o tratamento ou profilaxia de doenças do sistema nervoso central e desordens psicossomáticas incluindo síndrome de ansiedade, desordem de ansiedade particularmente generalizada, doença de pânico, ΕΡ 1 751 105/ΡΤ 5/5 doença compulsiva, fobia social, agorafobia, fobias em relação com situações especificas, desordem de stress, desordem de stress pós-traumático, desordem de memória pós-traumática, desordem cognitiva, disfunção sexual de origem no sistema nervoso central, depressão, esquizofrenia, neurodegeneração seguida de declínio mental, doença de Alzheimer, icto, demências, outras doenças gastrointestinais e doenças cardiovasculares, em particular hipertensão. Lisboa, 2009-01-29
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0400953A HUP0400953A3 (en) | 2004-05-11 | 2004-05-11 | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1751105E true PT1751105E (pt) | 2009-02-10 |
Family
ID=89982207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05745440T PT1751105E (pt) | 2004-05-11 | 2005-05-11 | Derivados de piperazina de alquil-oxindoles |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7910591B2 (pt) |
| EP (1) | EP1751105B1 (pt) |
| JP (1) | JP2007537227A (pt) |
| CN (1) | CN101010296B (pt) |
| AT (1) | ATE412633T1 (pt) |
| AU (1) | AU2005240843B2 (pt) |
| BG (1) | BG109769A (pt) |
| CA (1) | CA2566096A1 (pt) |
| CZ (1) | CZ2006779A3 (pt) |
| DE (1) | DE602005010693D1 (pt) |
| DK (1) | DK1751105T3 (pt) |
| EA (1) | EA010789B1 (pt) |
| ES (1) | ES2319795T3 (pt) |
| HR (1) | HRP20060420A2 (pt) |
| HU (1) | HUP0400953A3 (pt) |
| IL (1) | IL179028A (pt) |
| MX (1) | MXPA06013068A (pt) |
| NO (1) | NO20065609L (pt) |
| NZ (1) | NZ551545A (pt) |
| PL (2) | PL381615A1 (pt) |
| PT (1) | PT1751105E (pt) |
| RS (1) | RS20060621A (pt) |
| SI (1) | SI1751105T1 (pt) |
| SK (1) | SK51102006A3 (pt) |
| UA (1) | UA84927C2 (pt) |
| WO (1) | WO2005108364A1 (pt) |
| ZA (1) | ZA200610345B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0400953A3 (en) * | 2004-05-11 | 2008-02-28 | Egis Gyogyszergyar Nyilvanosan | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
| CN104163813B (zh) * | 2013-05-16 | 2017-02-01 | 广东东阳光药业有限公司 | 取代的吲哚化合物及其使用方法和用途 |
| CN106243088B (zh) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| FR2635104B1 (fr) * | 1988-08-03 | 1992-04-30 | Synthelabo | Derives d'indolone, leur preparation et leur application en therapeutique |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| WO1998008816A1 (fr) * | 1996-08-26 | 1998-03-05 | Meiji Seika Kaisha, Ltd. | Derives d'indoxyle et psychotropes |
| HUP0400953A3 (en) * | 2004-05-11 | 2008-02-28 | Egis Gyogyszergyar Nyilvanosan | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
-
2004
- 2004-05-11 HU HU0400953A patent/HUP0400953A3/hu unknown
-
2005
- 2005-05-11 EA EA200602084A patent/EA010789B1/ru not_active IP Right Cessation
- 2005-05-11 AU AU2005240843A patent/AU2005240843B2/en not_active Expired - Fee Related
- 2005-05-11 CN CN2005800148934A patent/CN101010296B/zh not_active Expired - Fee Related
- 2005-05-11 SI SI200530564T patent/SI1751105T1/sl unknown
- 2005-05-11 NZ NZ551545A patent/NZ551545A/en unknown
- 2005-05-11 CZ CZ20060779A patent/CZ2006779A3/cs unknown
- 2005-05-11 MX MXPA06013068A patent/MXPA06013068A/es active IP Right Grant
- 2005-05-11 DK DK05745440T patent/DK1751105T3/da active
- 2005-05-11 PL PL381615A patent/PL381615A1/pl unknown
- 2005-05-11 SK SK5110-2006A patent/SK51102006A3/sk not_active Application Discontinuation
- 2005-05-11 PL PL05745440T patent/PL1751105T3/pl unknown
- 2005-05-11 ZA ZA200610345A patent/ZA200610345B/en unknown
- 2005-05-11 EP EP05745440A patent/EP1751105B1/en active Active
- 2005-05-11 DE DE602005010693T patent/DE602005010693D1/de active Active
- 2005-05-11 PT PT05745440T patent/PT1751105E/pt unknown
- 2005-05-11 AT AT05745440T patent/ATE412633T1/de active
- 2005-05-11 RS RSP-2006/0621A patent/RS20060621A/sr unknown
- 2005-05-11 UA UAA200613076A patent/UA84927C2/ru unknown
- 2005-05-11 JP JP2007512357A patent/JP2007537227A/ja not_active Ceased
- 2005-05-11 ES ES05745440T patent/ES2319795T3/es active Active
- 2005-05-11 US US11/596,465 patent/US7910591B2/en not_active Expired - Fee Related
- 2005-05-11 CA CA002566096A patent/CA2566096A1/en not_active Abandoned
- 2005-05-11 WO PCT/HU2005/000050 patent/WO2005108364A1/en active Application Filing
-
2006
- 2006-11-02 IL IL179028A patent/IL179028A/en not_active IP Right Cessation
- 2006-12-04 HR HR20060420A patent/HRP20060420A2/xx not_active Application Discontinuation
- 2006-12-05 NO NO20065609A patent/NO20065609L/no not_active Application Discontinuation
- 2006-12-11 BG BG109769A patent/BG109769A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6272967B2 (ja) | ピルビン酸キナーゼ活性化剤の使用方法 | |
| WO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| ES2216266T3 (es) | 1-fenil-4-bencilpiperazinas: ligandos especificos del subtipo receptorde dopamina d4. | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| CN1284948A (zh) | 治疗活性化合物中的儿茶酚的吲唑生物等排物置换 | |
| ZA200309005B (en) | New indole derivatives with 5-HT6 receptor affinity. | |
| EP2726485A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| DE602005008558D1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen | |
| FR2567885A1 (fr) | Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant | |
| ES2963111T3 (es) | Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G | |
| AR035521A1 (es) | Derivados de 3-indolina y composicion farmaceutica que los comprende | |
| BR112012003741B1 (pt) | Derivados de cromona, um processo para seu preparo e suas aplicacoes terapêuticas | |
| WO2004048332A1 (ja) | イソインドリン誘導体 | |
| FR2635104A1 (fr) | Derives d'indolone, leur preparation et leur application en therapeutique | |
| WO2010086484A1 (es) | Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparación de nuevos derivados | |
| US20100029682A1 (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
| KR20110013381A (ko) | 퀴나졸린 유도체 | |
| AU2018246341B2 (en) | Compounds useful as inhibitors of ALCAT 1 | |
| PT1751105E (pt) | Derivados de piperazina de alquil-oxindoles | |
| EP0527081B1 (fr) | Nouvelles pipérazinylalcoyl-3 dihydro-2,3 4H-benzoxazine-1,3 ones-4 substituées, leur préparation et leur application en thérapeutique | |
| AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
| AR029461A1 (es) | Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento | |
| JPH06509318A (ja) | トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物 | |
| KR20170139036A (ko) | 헤테로시클릭-이미다졸계 화합물, 그 약물 조성물 및 그 제조방법과 용도 | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. |